NEWSAND NEW DRUGS 2014

SAMIR EL ANSARY

New Drug Approval

• Dalvance (dalbavancin) received FDA approval for IV use in the treatment

of MRSA skin and soft tissue infections

• Course of therapy would require 2 doses given 1 week apart

New Drug Approval

• Sivextro (tedizolid)

• Approved for skin and soft tissue infections caused by MRSA

• IV and PO formulations will be available

• Daily dosing x 6 days

New Drug Approval

• Afrezza (insulin human) inhalation powder

• Approved for use in adults with diabetes

• Rapid-acting orally inhaled insulin

• Administered at the beginning of each meal

New Drug Approval

• Jublia (efinaconazole)

• Approved for the treatment onychomyosis of the toenail

• 10% topical solution

• Apply once daily to clean dry toenails. Wait for at least 10 minutes after

showering, bathing, or washing before applying. Use for 24-48 weeks…

New Drug Approval

• Nasocobal (B12 supplementation nasal spray) approved by FDA

• Single-use devices for which the dosing is 500mcg (one spray) once weekly

• New DEVICE… “our new single-use device does NOT require priming…eliminates product loss…permits patients to conveniently receive

their dose with one spray per disposable device”

New Clinical Finding

• Metformin• may benefit African Americans more than

“European Americans”

• A1c percentages decreased more in African American individuals

• Unsure if this translates to less complications from diabetes

GOOD LUCK

SAMIR EL ANSARY

ICU PROFESSOR

AIN SHAMS

CAIRO